Get the Stockscreener App
5.365
7.30%
0.365
After Hours:
5.02
-0.345
-6.43%
Annexon Inc stock is traded at $5.365, with a volume of 2.17M.
It is up +7.30% in the last 24 hours and up +5.40% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.00
Open:
$5.12
24h Volume:
2.17M
Relative Volume:
0.81
Market Cap:
$799.68M
Revenue:
-
Net Income/Loss:
$-207.02M
P/E Ratio:
-3.8106
EPS:
-1.4079
Net Cash Flow:
$-176.59M
1W Performance:
-1.01%
1M Performance:
+5.40%
6M Performance:
+92.29%
1Y Performance:
+117.21%
1-Day Range:
$5.09
$5.52
1-Week Range:
$4.95
$5.62
52-Week Range:
$1.285
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.365 | 745.28M | 0 | -207.02M | -176.59M | -1.4079 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon (NASDAQ:ANNX) Trading Up 10.2%What's Next? - MarketBeat
Are Healthcare Stocks Falling Behind American Well (AMWL) in Performance This Year? - Bitget
Are Medical Stocks Lagging American Well (AMWL) This Year? - Yahoo Finance
If You Invested $1,000 in Annexon, Inc. (ANNX) - Stock Titan
ANNX PE Ratio & Valuation, Is ANNX Overvalued - Intellectia AI
Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER TrialsSlideshow (NASDAQ:ANNX) 2026-03-20 - Seeking Alpha
Chardan Capital Maintains Buy Rating on Annexon (ANNX) with $16 - GuruFocus
Annexon's (ANNX) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
H.C. Wainwright reiterates Buy on Annexon stock, $14 target By Investing.com - Investing.com Canada
Annexon Inc to Host KOL Event Transcript - GuruFocus
ANNX Earnings History & Surprises | EPS & Revenue Results | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4 - MarketBeat
ANNX: Phase III trial for C1q inhibition in GA is fully enrolled, with results expected in Q4 - TradingView
ANNX: Phase III trial for C1q inhibition in GA targets vision preservation with robust clinical design - TradingView
Portfolio Update: Will Annexon Inc benefit from government policyWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Annexon reports inducement grant to new employee under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ANNX SEC FilingsAnnexon, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Wall Street Recap: Is Annexon Inc in a bullish channel2026 Macro Moves & Technical Confirmation Alerts - baoquankhu1.vn
Insider Buying: William Carson Acquires 8,000 Shares of Annexon Inc (ANNX) - GuruFocus
William Carson Acquires 8,000 Shares of Annexon (NASDAQ:ANNX) Stock - MarketBeat
[Form 4] Annexon, Inc. Insider Trading Activity - Stock Titan
Annexon (NASDAQ:ANNX) Stock Price Down 8.1%Should You Sell? - MarketBeat
Annexon (NASDAQ:ANNX) Shares Up 6.8%Time to Buy? - MarketBeat
Rhenman & Partners Asset Management AB Boosts Holdings in Annexon, Inc. $ANNX - MarketBeat
Annexon (ANNX) CFO Lew sells shares to cover RSU tax withholding - Stock Titan
Annexon, Inc. (ANNX) CMO sells shares to cover tax obligations - Stock Titan
Annexon (ANNX) EVP Overdorf sells shares to cover RSU tax - Stock Titan
Annexon (ANNX) EVP sells 5,566 shares to cover RSU tax withholding - Stock Titan
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference - MarketBeat
ANNX: Late-stage neuroinflammatory programs near key data and filings, with strong commercial focus - TradingView
Director files sale notice for 5,566 ANNX shares (NASDAQ: ANNX) - Stock Titan
ANNX (NASDAQ: ANNX) Rule 144 notice shows 5,894 shares to be sold; prior 5,290 sold - Stock Titan
ANNX (NASDAQ) Rule 144: Insider sale of 6,225 shares; 4,339 vested - Stock Titan
ANNX (NASDAQ: ANNX) Form 144 lists 5,565-share notice and recent insider sale - Stock Titan
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
ANNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Annexon Showcases Promising Drug Ahead of Pivotal Trial Data - StocksToTrade
Annexon Showcases Emerging Treatment with Topline Data on Horizon - timothysykes.com
ANNX Technical Analysis & Stock Price Forecast - Intellectia AI
Annexon Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Does Annexon Inc. meet Warren Buffett’s criteriaEarnings Performance Report & Weekly Watchlist for Consistent Profits - mfd.ru
ANNX (NASDAQ: ANNX) insider sale notice: 5,820 shares tied to vesting - Stock Titan
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference - Investing News Network
Annexon (ANNX) CFO receives 250,000 options and 62,500 RSUs in equity grant - Stock Titan
Annexon (ANNX) grants CMO 225,000 options and 56,250 RSUs - Stock Titan
Jamie Dananberg Sells 5,290 Shares of Annexon (NASDAQ:ANNX) Stock - MarketBeat
Insider Selling: Annexon (NASDAQ:ANNX) EVP Sells 5,290 Shares of Stock - MarketBeat
Annexon (NASDAQ:ANNX) EVP Sells $40,149.27 in Stock - MarketBeat
Annexon (NASDAQ:ANNX) CFO Sells $40,118.61 in Stock - MarketBeat
Annexon (ANNX) EVP sells 7,857 shares to cover RSU tax withholding - Stock Titan
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):